(Hedgeweek) Pfizer CEO Albert Bourla has defended the drugmaker’s turnaround strategy in response to criticism from activist hedge fund firm Starboard Value, after reporting stronger-than-expected quarterly profits on the back of robust sales of its Covid-19 treatment Paxlovid, according to a report by Reuters.
Pfizer CEO defends strategy amid Starboard pressure
This entry was posted in Syndicated. Bookmark the permalink.
